AqueSys, a life sciences firm focusing on developing treatments for glaucoma, has secured $43.6m in its series D round, according to a SEC filing.

Backers in the round include venture firms Accuitive Medical Ventures, Longitude Capital, Rho Ventures, and SV Life Sciences. Private equity firm the Carlyle Group also backed the round.

All the backers in the latest round also participated in a series C held in 2010 worth $35m. In total, AqueSys has received upwards of $78m in…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?